A comprehensive new meta-analysis provides reassurance for expectant parents: based on data from more than 40 high-quality studies, researchers found no evidence that paracetamol use during pregnancy increases the risk of autism, ADHD or intellectual disability in children, reinforcing current medical guidance on its safe use.
Professor Asma Khalil and colleagues found that taking paracetamol during pregnancy is not associated with an increased risk of autism, ADHD or intellectual disability in children, based on a large systematic review and meta-analysis of high-quality studies.
(Source: Professor Asma Khalil)
Taking paracetamol during pregnancy does not increase the risk of autism, attention-deficit hyperactivity disorder (ADHD), or intellectual disability among children. That is according to the most rigorous analysis of the evidence to date published in The Lancet Obstetrics, Gynaecology & Women’s Health, and led by researchers from City St George’s, University of London.
Researchers conducted a systematic review and meta-analysis of 43 existing studies to determine whether paracetamol was safe to use in pregnancy or not. This was in response to public concerns following claims back in September 2025 that suggested taking paracetamol during pregnancy might impact the neurodevelopment of those children and increase their risk of autism.
The claims were based on earlier studies that reported small associations between paracetamol in pregnancy and increased risks of autism. However, these were often based on studies prone to biases, including being limited by the type of data collected and not exploring comparisons between siblings to account for family history, which is vital information.
The team looked at 43 studies with the highest quality and most rigorous research methods and compared pregnancies where the mother had taken paracetamol to pregnancies where they had not taken the drug.
They pooled the results of sibling comparison studies that compared siblings born to the same mother, where one pregnancy involved paracetamol exposure and another did not. This design helps control for shared genetics, family environment and long-term parental characteristics that traditional studies cannot fully account for.
Across the sibling-comparison studies, data included 262,852 children assessed for autism, 335,255 for ADHD and 406,681 for intellectual disability. When compared to pregnancies with no exposure to paracetamol, it was confirmed that taking paracetamol in pregnancy was not linked to childhood autism, ADHD or intellectual disability.
Our findings suggest that previously reported links are likely to be explained by genetic predisposition or other maternal factors such as fever or underlying pain, rather than a direct effect of the paracetamol itself.
Professor Asma Khalil
Professor Asma Khalil, Professor of Obstetrics and Maternal Fetal Medicine at City St George’s, University of London and Consultant Obstetrician, who led the study said: “The message is clear — paracetamol remains a safe option during pregnancy when taken as guided. This is important as paracetamol is the first-line medication we recommend for pregnant women in pain or with a fever, and so they should feel reassured that they still have a safe option to relieve them of their symptoms.”
All studies were assessed for their quality based on the Quality In Prognosis Studies (QUIPS) tool that evaluates numerous factors in the way the research has been conducted to determine the risk of bias, another strength of this work. The lack of association between taking paracetamol during pregnancy and the risk of the child having autism, ADHD or intellectual disabilities also remained in the studies deemed to be at low risk of bias (and therefore highest quality), and in those which had a longer follow-up period of over five years.
The authors note that a limitation of the current study was that it was not possible to analyse smaller groups in the studies with sibling comparisons based on which trimester of pregnancy paracetamol was consumed in, sex of the baby or how often paracetamol was taken, because too few of the existing studies reported these data.
Overall, the findings of the study support the recommendations made by major medical organisations worldwide. The researchers hope that this gold-standard review will put an end to any scepticism on using paracetamol during pregnancy as avoiding paracetamol for significant pain or fever can expose both mother and baby to known risks, particularly untreated maternal fever.
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
Original Article: Prenatal paracetamol exposure and child neurodevelopment: a systematic review and meta-analysis; The Lancet, DOI:10.1016/S3050-5038(25)00211-0